White Paper

Biosafety Testing And Quality Control Requirements For Lentiviral Vectors With A Focus On Replication Competent Testing And Infectious Titer

Pipette With Cell Culture Plate iStock-520238063

The use of lentiviral (LV) vectors to deliver genetic material in the treatment of diseases refractory to other therapies has become a familiar and successful form of gene therapy over the past decade. Most frequently based on human immunodeficiency virus (HIV), LV vectors have a large genetic capacity with relatively low immunogenicity and a preference for transducing cells that are non-proliferating or are slowly proliferating. This latter attribute not only increases the possibility of persistence of the gene modified cells but may also reduce oncogenic potential.

Due to the unique nature and application of lentiviral vectors, it is critical to plan for, and properly perform the complete testing requirements to ensure safety and consistency of your LV based ex vivo gene therapy. Interpreting and applying the relevant regulations and guidelines can be a challenge, but with the right expertise and guidance you can avoid unwelcome surprises and reduce the time it takes for your therapy to reach awaiting patients.

In this paper we cover the key manufacturing principles of LV vectors, regulatory considerations specific to the testing requirements of LV vectors, and testing strategies for LV vectors, with particular focus on the replication competent virus assay and infectious titer assay.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online